Navigation Links
MultiVu Video Feed: Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
Date:1/23/2009

Geron to Study GRNOPC1 in Patients with Acute Spinal Cord Injury

Geron Corporation (Nasdaq: GERN) announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury. The clearance enables Geron to move forward with the world's first study of a human embryonic stem (hESC) cell-based therapy in man.

Geron plans to initiate a Phase I multicenter trial that is designed to establish the safety of GRNOPC1 in patients with "complete" American Spinal Cord Injury Association (ASIA) Grade A subacute thoracic spinal cord injuries. Patients eligible for the Phase I trial must have documented evidence of functionally complete spinal cord injury with a neurological level of T3 to T10 spinal segments and agree to have GRNOPC1 injected into the lesion sites between seven and 14 days after injury.

    For more information about GRNOPC1, please visit:http://www.geron.com

    SATELLITE FEEDS:
    Friday, January 23rd, 2009         Friday, January 23rd, 2009
    9:30 AM - 9:45 AM ET               1:15 PM - 1:30 PM ET
    Galaxy 3C                          Galaxy 3C
    C-Band                             C-Band
    Transponder 8                      Transponder 8
    Downlink Freq. 3860 Vertical       Downlink Freq. 3860 Vertical

Preview and access this video on Pathfire DMG: Slug # 33040

Search within the PR Newswire or MultiVu section by story ID # 33040 or by headline

For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail support@pathfire.com

NEWS: World's First Study of Human Embryonic Stem Cell-Based Therapy In Man

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/33040/press.html


    SOUNDBITES:
    * Thomas B. Okarma, Ph.D., M.D., President, CEO and Director, Geron
      Corporation

    B-ROLL INCLUDES:
    * spinal cord cell therapy animation
    * lab and manufacturing footage
    * Geron office building exterior shots

VIDEO PROVIDED BY: Geron Corporation

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


'/>"/>
SOURCE Geron Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) --
2. MultiVu Video Feed: New Rapid Test to Diagnose Flu May Help With Upcoming Flu Season
3. MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care
4. MultiVu Video Feed: Easypod(R), Award-Winning Electronic Device
5. MultiVu Video Feed: Hard Rocks 2007 Ambassadors of Rock Tour Is "On the Road Again" With Music Legend Willie Nelson
6. MultiVu Video Feed: Allergan, Inc. Partners With "Project Runway" Designer Kara Saun and Gen Art Fresh Faces In Fashion to Raise Awareness About Excessive Underarm Sweating
7. New Video Streaming Site Created by Ambrose Video Publishing
8. Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
9. New Online Video Features Brazilian Researcher Elbio Rech
10. Video: 8-Minute Film Documentary Explores Why Humans Age
11. PharmSource President Moderates Videocast on Outsourcing to Asia at AAPS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):